Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vikas Patil

Showing results (81-90 of 89) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 89 results.
Neuro-Oncology|May 17, 2026
Modern Molecular Profiling Recontextualizes the NRG/RTOG 0539 Trial and Reveals Hidden High-Risk and Radiotherapy Resistant MeningiomasLeeor S Yefet, Alexander P Landry, C Leland Rogers, et al.
Journal of Medicinal Chemistry|May 10, 2014
Novel N-linked aminopiperidine-based gyrase inhibitors with improved hERG and in vivo efficacy against Mycobacterium tuberculosisShahul Hameed P, Vikas Patil, Suresh Solapure, et al.
Neuro-Oncology|November 6, 2024
Validation and next-generation update of a DNA methylation-based recurrence predictor for meningioma: A multicenter prospective studyAlexander P Landry, Justin Z Wang, Vikas Patil, et al.
Nature Medicine|August 21, 2024
Molecular classification to refine surgical and radiotherapeutic decision-making in meningiomaJustin Z Wang, Vikas Patil, Alexander P Landry, et al.
Nature Medicine|July 21, 2025
Author Correction: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trialFarshad Nassiri, Vikas Patil, Leeor S Yefet, et al.
Nature Medicine|May 15, 2023
Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trialFarshad Nassiri, Vikas Patil, Leeor S Yefet, et al.
Journal of Medicinal Chemistry|June 11, 2014
Aminoazabenzimidazoles, a novel class of orally active antimalarial agentsShahul Hameed P, Murugan Chinnapattu, Gajanan Shanbag, et al.
Nature Communications|April 1, 2015
Triaminopyrimidine is a fast-killing and long-acting antimalarial clinical candidateShahul Hameed P, Suresh Solapure, Vikas Patil, et al.
Cell|July 6, 2024
Early rhombic lip Protogenin<sup>+ve</sup> stem cells in a human-specific neurovascular niche initiate and maintain group 3 medulloblastomaAbhirami Visvanathan, Olivier Saulnier, Chuan Chen, et al.
Pageof 9

Showing results (81-90 of 89) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 89 results.
Neuro-Oncology|May 17, 2026
Modern Molecular Profiling Recontextualizes the NRG/RTOG 0539 Trial and Reveals Hidden High-Risk and Radiotherapy Resistant MeningiomasLeeor S Yefet, Alexander P Landry, C Leland Rogers, et al.
Journal of Medicinal Chemistry|May 10, 2014
Novel N-linked aminopiperidine-based gyrase inhibitors with improved hERG and in vivo efficacy against Mycobacterium tuberculosisShahul Hameed P, Vikas Patil, Suresh Solapure, et al.
Neuro-Oncology|November 6, 2024
Validation and next-generation update of a DNA methylation-based recurrence predictor for meningioma: A multicenter prospective studyAlexander P Landry, Justin Z Wang, Vikas Patil, et al.
Nature Medicine|August 21, 2024
Molecular classification to refine surgical and radiotherapeutic decision-making in meningiomaJustin Z Wang, Vikas Patil, Alexander P Landry, et al.
Nature Medicine|July 21, 2025
Author Correction: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trialFarshad Nassiri, Vikas Patil, Leeor S Yefet, et al.
Nature Medicine|May 15, 2023
Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trialFarshad Nassiri, Vikas Patil, Leeor S Yefet, et al.
Journal of Medicinal Chemistry|June 11, 2014
Aminoazabenzimidazoles, a novel class of orally active antimalarial agentsShahul Hameed P, Murugan Chinnapattu, Gajanan Shanbag, et al.
Nature Communications|April 1, 2015
Triaminopyrimidine is a fast-killing and long-acting antimalarial clinical candidateShahul Hameed P, Suresh Solapure, Vikas Patil, et al.
Cell|July 6, 2024
Early rhombic lip Protogenin<sup>+ve</sup> stem cells in a human-specific neurovascular niche initiate and maintain group 3 medulloblastomaAbhirami Visvanathan, Olivier Saulnier, Chuan Chen, et al.
Pageof 9